But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ApexOnco Front Page
Recent articles
2026’s first big oncology buyout is here.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company is starting four new pivotal trials this year.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
